Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms

Molecular Pharmaceutics

Volumn 8, Issue 4, 2011, Pages 1063-1072

  Clementi, Chiara ^a   Miller, Keren ^b   Mero, Anna ^a   Satchi Fainaro, Ronit ^b   Pasut, Gianfranco ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CREMOPHOR; DENDRIMER; HYDROXYAPATITE; MACROGOL; PACLITAXEL;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BONE CANCER; BONE METASTASIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; OSTEOPOROSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ALENDRONATE; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DENDRIMERS; DRUG CARRIERS; FEMALE; HEMOLYSIS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PACLITAXEL; POLYETHYLENE GLYCOLS; RATS;

EID: 79961076051     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp2001445     Document Type: Article

References (39)

1. Duncan, R. Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 2006, 6, 688-701 (Pubitemid 44286001)
2. Moses, M. A.; Brem, H.; Langer, R. Advancing the field of drug delivery: taking aim at cancer Cancer Cell 2003, 4, 337-41 (Pubitemid 37491094)
3. Vasey, P. A.; Kaye, S. B.; Morrison, R.; Twelves, C.; Wilson, P.; Duncan, R.; Thomson, A. H.; Murray, L. S.; Hilditch, T. E.; Murray, T.; Burtles, S.; Fraier, D.; Frigerio, E.; Cassidy, J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee Clin. Cancer Res. 1999, 5, 83-94 (Pubitemid 29045181)
4. Zhao, H.; Rubio, B.; Sapra, P.; Wu, D.; Reddy, P.; Sai, P.; Martinez, A.; Gao, Y.; Lozanguiez, Y.; Longley, C.; Greenberger, L. M.; Horak, I. D. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers Bioconjugate Chem. 2008, 19, 849-859 (Pubitemid 351614540)
5. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000, 65, 271-284 (Pubitemid 30122932)
6. Kunath, K.; Kopecková, P.; Minko, T.; Kopecek, J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line Eur. J. Pharm. Biopharm. 2000, 49, 11-15 (Pubitemid 30009941)
7. Pasut, G.; Canal, F.; Dalla Via, L.; Arpicco, S.; Veronese, F. M.; Schiavon, O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid J. Controlled Release 2008, 127, 239-248
8. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2002, 2, 750-763 (Pubitemid 37328910)
9. Brumlik, M. J.; Daniel, B. J.; Waehler, R.; Curiel, D. T.; Giles, F. J.; Curiel, T. J. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy Expert Opin. Drug Delivery 2008, 5, 87-103 (Pubitemid 351234111)
10. Segal, E.; Pan, H.; Ofek, P.; Udagawa, T.; Kopecková, P.; Kopecek, J.; Satchi-Fainaro, R. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics PLoS ONE 2009, 4, e5233
11. Canal, F.; Vicent, M. J.; Pasut, G.; Schiavon, O. Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates J. Controlled Release 2010, 146, 388-399
12. Vicent, M. J.; Greco, F.; Nicholson, R. I.; Paul, A.; Griffiths, P. C.; Duncan, R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer Angew. Chem., Int. Ed. Engl. 2005, 44 (26) 4061-4066 (Pubitemid 40886448)
13. Pasut, G.; Greco, F.; Mero, A.; Mendichi, R.; Fante, C.; Green, R. J.; Veronese, F. M. Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action J. Med. Chem. 2009, 52, 6499-6502
14. Greco, F.; Vicent, M. J. Combination therapy: opportunities and challenge for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Delivery Rev. 2009, 61, 1203-1213
15. Miller, K.; Erez, R.; Segal, E.; Shabat, D.; Satchi-Fainaro, R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate Angew. Chem., Int. Ed. Engl. 2009, 48, 2949-2954
16. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 2001, 37, 1590-1598 (Pubitemid 32778603)
17. Rowinsky, E. K.; Donehower, R. C. Paclitaxel (Taxol) New Engl. J. Med. 1995, 332, 1004-1014
18. Straubinger, R. M. Biophamaceutics of paclitaxel (Taxol): formulation, activity and pharmacokinetics. In Taxol: science and applications; Suffness, M., Ed.; CRC Press: Boca Raton, FL, 1996; pp 237-258.
19. Wang, D.; Sima, M.; Mosley, R. L.; Davda, J. P.; Tietze, N.; Miller, S. C.; Gwilt, P. R.; Kopeckova, P.; Kopecek, J. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl) methacrylamide copolymers Mol. Pharmaceutics 2006, 3, 717-25 (Pubitemid 46087487)
20. Uludag, H. Bisphosphonates as a foundation of drug delivery to bone Curr. Pharm. Des. 2002, 8, 1929-1944
21. Caraglia, M.; Santini, D.; Marra, M.; Vincenzi, B.; Tonini, G.; Budillon, A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates Endocr. Relat. Cancer 2006, 13, 7-26
22. Snyder, S. L.; Sobocinski, P. Z. An improved 2,4,6- trinitrobenzenesulfonic acid method for the determination of amines Anal. Biochem. 1975, 64, 284-288
23. Pasut, G.; Scaramuzza, S.; Schiavon, O.; Mendichi, R.; Veronese, F. M. PEG-epirubicin conjugates with high loading J. Bioacct. Compat. Polym. 2005, 20, 213-230
24. Kuljanin, J.; Jankovic, I.; Nedeljkovic, J.; Prstojevic, D.; Marinkovic, V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions J. Pharm. Biomed. Anal. 2002, 28, 1215-1220 (Pubitemid 34607407)
25. Duncan, R.; Ferruti, P.; Sgouras, D.; Tuboku-Metzger, A.; Ranucci, E.; Bignotti, F. A polymer-Triton X-100 conjugate capable of PH-dependent red blood cell lysis: a model system illustrating the possibility of drug delivery within acidic intracellular compartments J. Drug Target. 1994, 2, 341-347 (Pubitemid 24351015)
26. Ofek, P.; Fischer, W.; Calderon, M.; Haag, R.; Satchi-Fainaro, R. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers FASEB J. 2010, 24, 3122-3134
27. Bilensoy, E.; Gurkaynak, O.; Dogan, A. L.; Hincal, A. A. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery Int. J. Pharm. 2008, 347, 163-170 (Pubitemid 350180328)
28. Cetnar, J. P.; Malkowicz, S. B.; Palmer, S. C.; Wein, A. J.; Vaughn, D. J. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer Urology 2008, 71, 942-946
29. Sanfilippo, N. J.; Taneja, S. S.; Chachoua, A.; Lepor, H.; Formenti, S. C. Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer J. Clin. Oncol. 2008, 26, 2973-2978
30. Bhalla, K. N. Microtubule-targeted anticancer agents and apoptosis Oncogene 2003, 22, 9075-9086 (Pubitemid 38121708)
31. Wang, D.; Miller, S.; Sima, M.; Kopecková, P.; Kopecek, J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems Bioconjugate Chem. 2003, 14, 853-859 (Pubitemid 37157997)
32. 3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases Bioconjugate Chem. 2010, 21, 811-815
33. Duncan, R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt Adv. Drug Delivery Rev. 2009, 61, 1131-1148
34. Satchi, R.; Connors, T. A.; Duncan, R. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination Br. J. Cancer 2001, 85, 1070-1076 (Pubitemid 33016011)
35. Satchi-Fainaro, R.; Puder, M.; Davies, J. W.; Tran, H. T.; Sampson, D. A.; Greene, A. K.; Corfas, G.; Folkman, J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 Nat. Med. 2004, 10, 255-261 (Pubitemid 38667615)
36. Veronese, F. M.; Schiavon, O.; Pasut, G.; Mendichi, R.; Andersson, L.; Tsirk, A.; Ford, J.; Wu, G.; Kneller, S.; Davies, J.; Duncan, R. PEG-Doxorubicin Conjugates: Influence of Polymer Structure on Drug Release, in Vitro Cytotoxicity, biodistribution, and Antitumor Activity Bioconjugate Chem. 2005, 16, 775-784 (Pubitemid 41026163)
37. Andersson, L.; Davies, J.; Duncan, R.; Ferruti, P.; Ford, J.; Kneller, S.; Mendichi, R.; Pasut, G.; Schiavon, O.; Summerford, C.; Tirk, A.; Veronese, F. M.; Vincenzi, V.; Wu, G. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates Biomacromolecules 2005, 6, 914-926 (Pubitemid 40467837)
38. Hrubý, M.; Etrych, T.; Kučka, J.; Forsterová, M.; Ulbrich, K. Hydroxybisphosphonate-containing polymeric drug-delivery systems designed for targeting into bone tissue J. Appl. Polym. Sci. 2006, 101, 3192-3201 (Pubitemid 44220960)
39. Maddox, D. A; Deen, W. M; Brenner, B. M. Glomerular filtration. In Handbook of Physiology. Renal Physiology; American Physiological Society: Bethesda, MD, 1992; sect. 8, Vol. I, 13, pp 545-638.